Thread by @ZdenekVrozina

Long COVID research badly needs studies that move beyond description and toward intervention. This is why this preprint is worth attention. It starts to sketch a possible treatment path.🧵

A new preprint is interesting because it points to something important
a potentially treatable biological mechanism.
Not a clinical breakthrough. More like a promising preclinical proof of concept.

This study is a strong mechanistic signal that at least some of the neurological problems after COVID may be driven by persistent neuroinflammation - and that shifting immune regulation can improve that state in mice.

The authors tested an intranasal anti-CD3 antibody in a mouse model of post-COVID neuroinflammation.
What they observed was not just less inflammation, but a fairly coherent biological pattern.

Compared with control-treated post-COVID mice, anti-CD3 treatment reduced microglial and astrocytic cell density in the white matter and hippocampus, expanded Tregs, improved the neurogenic environment, and improved performance in a short-term memory task.

The most important point is this
the treatment did not work only when given early after infection.
It also worked when given later, after neuroinflammation was already established.
And that is exactly why the study stands out.

That point matters for Long COVID because patients usually do not present during the acute phase of infection. They present weeks or months later, when symptoms persist.
So this is not just a prevention story.
It raises the possibility - still hypothetical - of treating an already established post-infectious state.

At the same time, proportion matters. This is a mouse model, a preprint, not a clinical trial. It is an encouraging biological study of mechanism and possible therapy.

Mechanistically, the paper suggests a fairly clear chain.
Intranasal anti-CD3 - more regulatory T cells/more IL-10 - less activated microglia and astrocytes - a better environment for hippocampal neurogenesis - improved short-term memory performance in mice.
That is what makes the study more than just another descriptive LC paper.

And this is where the most important open questions begin.
Because the treatment mechanism comes with a possible trade-off.
If the immune system is pushed in a more regulatory direction, could harmful neuroinflammation be reduced at the cost of other risks?

Could this increase susceptibility to infections?
Could it reactivate latent viruses?
Could long-term use weaken anti-tumor immune surveillance?

This is where caution matters. The Treg axis may be helpful when the goal is to calm harmful inflammation, but in theory it could also dampen immune control over emerging tumor cells. This paper does not answer that.

There is also a more reassuring side.
Intranasal foralumab has been described in a small study of healthy volunteers as showing immunological activity without observed adverse effects during short-term dosing.

The importance of this study is not that it has already delivered a treatment for Long COVID, but that it suggests post-COVID neuroinflammation may not be just a passive aftermath. It may be a biologically active process that can be modified.

The hope comes mainly from the fact that the effect was seen even with delayed treatment. It is an interesting preclinical proof of concept that opens a path for real testing.

Lu at al., Intranasal Anti-CD3 Antibody Treatment Attenuates Post-COVID Neuroinflammation and Enhances Hippocampal Neurogenesis and Cognitive Function in Mice. biorxiv.org/content/10.648…